Bio-Rad Laboratories (BIO) Stake Lessened by Asymmetry Capital Management L.P.

Asymmetry Capital Management L.P. lessened its stake in shares of Bio-Rad Laboratories (NYSE:BIO) by 67.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,511 shares of the medical research company’s stock after selling 9,283 shares during the quarter. Bio-Rad Laboratories comprises approximately 1.4% of Asymmetry Capital Management L.P.’s holdings, making the stock its 26th largest position. Asymmetry Capital Management L.P.’s holdings in Bio-Rad Laboratories were worth $1,128,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its stake in shares of Bio-Rad Laboratories by 297.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock worth $134,000 after acquiring an additional 419 shares in the last quarter. Private Advisor Group LLC bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth about $248,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bio-Rad Laboratories by 42.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock worth $278,000 after acquiring an additional 350 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Bio-Rad Laboratories during the 1st quarter worth about $280,000. Finally, Advisory Services Network LLC boosted its stake in shares of Bio-Rad Laboratories by 218.6% during the 4th quarter. Advisory Services Network LLC now owns 1,217 shares of the medical research company’s stock worth $290,000 after acquiring an additional 835 shares in the last quarter. Institutional investors own 65.55% of the company’s stock.

NYSE BIO opened at $291.71 on Thursday. Bio-Rad Laboratories has a twelve month low of $286.17 and a twelve month high of $293.43. The company has a quick ratio of 2.99, a current ratio of 4.33 and a debt-to-equity ratio of 0.10. The stock has a market cap of $8.55 billion, a P/E ratio of 71.15, a price-to-earnings-growth ratio of 3.12 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.22. Bio-Rad Laboratories had a return on equity of 3.84% and a net margin of 34.32%. The business had revenue of $620.43 million during the quarter, compared to analysts’ expectations of $618.89 million. analysts expect that Bio-Rad Laboratories will post 6.13 EPS for the current year.

Several analysts have recently issued reports on the company. Zacks Investment Research downgraded Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, May 8th. Jefferies Group boosted their price objective on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. ValuEngine raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. CL King cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a research report on Friday, February 16th. Finally, Wells Fargo cut their price objective on Bio-Rad Laboratories from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $297.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply